AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30214185 — intervention group
Group type: EXPERIMENTAL
Intervention: GFF MDI
Number of subjects: 20
Study 30214185 — intervention group
Group type: COMPARATOR
Intervention: Placebo MDI
Number of subjects: 20
Study 27619983 — intervention group
Group type: EXPERIMENTAL
Intervention: ipragliflozin (50-100 mg once daily)
Number of subjects: 480
Study 27619983 — intervention group
Group type: COMPARATOR
Intervention: control (continuation of conventional therapy)
Number of subjects: 480
Study 27619983 — intervention group
Group type: EXPERIMENTAL
Intervention: ipragliflozin
Number of subjects: 480
Study 27619983 — intervention group
Group type: COMPARATOR
Intervention: control
Number of subjects: 480
Study 24862215 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilpivirine long-acting (RPV-LA) 300 mg
Number of subjects: 66
Study 24862215 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilpivirine long-acting (RPV-LA) 600 mg
Number of subjects: 66
Study 24862215 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilpivirine long-acting (RPV-LA) 1,200 mg
Number of subjects: 66
Study 24862215 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 66
Study 22311939 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glycaemic index (Low GI) diet
Number of subjects: 23
Study 22311939 — intervention group
Group type: COMPARATOR
Intervention: Calorie restricted (Low Cal) diet
Number of subjects: 23
Study 20210844 — intervention group
Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 1253
Study 20210844 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 1253
Study 20210844 — intervention group
Group type: COMPARATOR
Intervention: Both genders
Number of subjects: 1253
Study 20210844 — intervention group
Group type: COMPARATOR
Intervention: Blood glucose level at randomization and updated glucose concentration during follow-up
Number of subjects: 1253
Study 18626654 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic scalpel (HS)
Number of subjects: 200
Study 18626654 — intervention group
Group type: COMPARATOR
Intervention: Knot tying technique (KT)
Number of subjects: 200
Study 16685882 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic skeleton guided evaluation of stenoses in human coronary arteries
Number of subjects: 0
Study 12628949 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril (10 mg daily)
Number of subjects: 9297
Study 12628949 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 9297
Study 12628949 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9297
Study 10776077 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradient ultrafiltration
Number of subjects: 20
Study 10776077 — intervention group
Group type: COMPARATOR
Intervention: Constant ultrafiltration
Number of subjects: 20
Study 9061125 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation (400 mL daily during hospital stay and 200 mL daily for 6 months at home)
Number of subjects: 46
Study 9061125 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation (SG-)
Number of subjects: 46
Study 9061125 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care without supplements)
Number of subjects: 46
Study 9061125 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation (SG+)
Number of subjects: 46
Study 9061125 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 46
Study 1900008 — intervention group
Group type: EXPERIMENTAL
Intervention: rt-PA
Number of subjects: 352
Study 1900008 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 352
Study 6091169 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine and low-dose prednisolone
Number of subjects: 145
Study 6091169 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporin A
Number of subjects: 145
Study 6091169 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary CMV infections
Number of subjects: 145
Study 6091169 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary CMV infections
Number of subjects: 145
Study 6091169 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV infection
Number of subjects: 145
Study 30786835 — intervention group
Group type: EXPERIMENTAL
Intervention: JVS-100 8 mg
Number of subjects: 109
Study 30786835 — intervention group
Group type: EXPERIMENTAL
Intervention: JVS-100 16 mg
Number of subjects: 109
Study 30786835 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study 30786835 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (JVS-100 and placebo)
Number of subjects: 109
Study 30786835 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 109
Study 29966016 — intervention group
Group type: EXPERIMENTAL
Intervention: SRLS 100 mg
Number of subjects: 99
Study 29966016 — intervention group
Group type: EXPERIMENTAL
Intervention: SRLS 200 mg
Number of subjects: 99
Study 29966016 — intervention group
Group type: EXPERIMENTAL
Intervention: SRLS 400 mg
Number of subjects: 99
Study 29966016 — intervention group
Group type: COMPARATOR
Intervention: PLGA 100 mg
Number of subjects: 99
Study 29966016 — intervention group
Group type: COMPARATOR
Intervention: Non-administration group
Number of subjects: 99
Study 26949137 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone plus Salmeterol
Number of subjects: 11679
Study 26949137 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone alone
Number of subjects: 11679
Study 25278810 — intervention group
Group type: EXPERIMENTAL
Intervention: King Vision™ video laryngoscope (KV group)
Number of subjects: 60
Study 25278810 — intervention group
Group type: COMPARATOR
Intervention: Conventional blind insertion (Blind group)
Number of subjects: 60
Study 22507696 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring
Number of subjects: 205
Study 22507696 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 205
Study 20586676 — intervention group
Group type: EXPERIMENTAL
Intervention: New adjustable length titanium ossicular prosthesis (ALTO)
Number of subjects: 14
Study 20586676 — intervention group
Group type: COMPARATOR
Intervention: Control group (age- and pathology-matched)
Number of subjects: 14
Study 17433902 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral formulations of female hormone replacement
Number of subjects: 0
Study 17433902 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive
Number of subjects: 0
Study 17433902 — intervention group
Group type: EXPERIMENTAL
Intervention: Heritable and acquired risk factors for thrombosis
Number of subjects: 0
Study 15827780 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) with mitomycin C (35 mg/m2) at 40-41 degrees C for 90 minutes
Number of subjects: 117
Study 15827780 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete cytoreduction
Number of subjects: 117
Study 15827780 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal residual disease
Number of subjects: 117
Study 15827780 — intervention group
Group type: EXPERIMENTAL
Intervention: Gross macroscopic tumor left behind
Number of subjects: 117
Study 12221381 — intervention group
Group type: COMPARATOR
Intervention: 20% benzocaine gel
Number of subjects: 20
Study 12221381 — intervention group
Group type: COMPARATOR
Intervention: 60% lidocaine gel
Number of subjects: 20
Study 10547222 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (TMZ) 40 mg orally 15 minutes before thrombolysis, followed by 20 mg every 8 hours
Number of subjects: 81
Study 10547222 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (TMZ)
Number of subjects: 81
Study 10547222 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 7599825 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline
Number of subjects: 0
Study 7599825 — intervention group
Group type: COMPARATOR
Intervention: Fatigue (without aminophylline)
Number of subjects: 0
Study 2136870 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (n = 27)
Number of subjects: 44
Study 2136870 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine (n = 17)
Number of subjects: 44
Study 692838 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluphenazine decanoate
Number of subjects: 39
Study 692838 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluphenazine enanthate
Number of subjects: 39
Study 31766063 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvement of 25(OH)D levels from <75 nmol/l to ≥75 nmol/l (median: 40.2 nmol/l to 83.2 nmol/l)
Number of subjects: 933
Study 31766063 — intervention group
Group type: COMPARATOR
Intervention: Control group with consistently <75 nmol/l 25(OH)D levels
Number of subjects: 933
Study 27714914 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone assessment
Number of subjects: 108
Study 27714914 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face assessment
Number of subjects: 108
Study 25909205 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 33
Study 25909205 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 33
Study 23392460 — intervention group
Group type: EXPERIMENTAL
Intervention: elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (EVG/COBI/FTC/TDF)
Number of subjects: 700
Study 23392460 — intervention group
Group type: COMPARATOR
Intervention: efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF)
Number of subjects: 700
Study 21311765 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid
Number of subjects: 39597
Study 21311765 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid with low prevalence of antiplatelet therapy (60% on average)
Number of subjects: 39597
Study 21311765 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid with high prevalence of antiplatelet therapy (91% on average)
Number of subjects: 39597
Study 21311765 — intervention group
Group type: COMPARATOR
Intervention: MTHFR gene mutation (CT)
Number of subjects: 39597
Study 19120433 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir
Number of subjects: 29
Study 19120433 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 29
Study 17284097 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (bolus of 1.0 microg/kg, continuous infusion from 0.25 to 0.05 microg/kg/min)
Number of subjects: 33
Study 17284097 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil (bolus of 10 microg/kg, continuous infusion from 2.0 to 0.5 microg/kg/min)
Number of subjects: 33
Study 17284097 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 33
Study 14997022 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum zinc levels
Number of subjects: 131
Study 14997022 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone mineral density (BMD) measurements
Number of subjects: 131
Study 14997022 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of lumbar BMD Z-scores in females with severe zinc deficiency
Number of subjects: 131
Study 14997022 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum zinc levels in females with femoral BMD Z-scores < -2
Number of subjects: 131
Study 16861150 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotropic analgesic nitrous oxide (PAN)
Number of subjects: 33
Study 16861150 — intervention group
Group type: COMPARATOR
Intervention: Oxygen (O2)
Number of subjects: 33
Study 16861150 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 9862845 — intervention group
Group type: EXPERIMENTAL
Intervention: Transjugular intrahepatic portosystemic shunt (TIPS)
Number of subjects: 46
Study 9862845 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic sclerotherapy (ES)
Number of subjects: 46
Study 8572836 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting
Number of subjects: 2365
Study 1827098 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 250 mg 12-hourly for 14 days
Number of subjects: 208
Study 1827098 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin stearate 500 mg 6-hourly for 14 days
Number of subjects: 208
Study 7178675 — intervention group
Group type: EXPERIMENTAL
Intervention: Neo‐Biphyllin Mikroklysma (400 mg Theophylline, 600 mg Diprophylline, 600 mg Proxyphylline)
Number of subjects: 8
Study 31376153 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Number of subjects: 162
Study 31376153 — intervention group
Group type: COMPARATOR
Intervention: Fumaric Acid Esters (FAEs)
Number of subjects: 162
Study 31376153 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 162
Study 31444714 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV testing (open testing)
Number of subjects: 270
Study 31444714 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to HIV care
Number of subjects: 270
Study 31444714 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender comparison
Number of subjects: 270
Study 29943872 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week knee extensor training program (twice-weekly, five sets of 12 stretches, 3 seconds per stretch)
Number of subjects: 26
Study 29943872 — intervention group
Group type: COMPARATOR
Intervention: Downhill run (20 minutes)
Number of subjects: 26
Study 26663394 — intervention group
Group type: EXPERIMENTAL
Intervention: Wet shaving with a razor followed by standard soap washing (SW)
Number of subjects: 30
Study 26663394 — intervention group
Group type: EXPERIMENTAL
Intervention: Waxing followed by standard soap washing (SW)
Number of subjects: 30
Study 26663394 — intervention group
Group type: EXPERIMENTAL
Intervention: Clipping with scissors followed by standard soap washing (SW)
Number of subjects: 30
Study 26663394 — intervention group
Group type: COMPARATOR
Intervention: Standard soap washing (SW) alone
Number of subjects: 30
Study 25436819 — intervention group
Group type: EXPERIMENTAL
Intervention: SRH intervention in public sector HIV care clinics
Number of subjects: 197
Study 22918392 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone consultation
Number of subjects: 6600
Study 22918392 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face consultation
Number of subjects: 6600
Study 20018300 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.5 microg/kg)
Number of subjects: 90
Study 20018300 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental (1 mg/kg)
Number of subjects: 90
Study 20018300 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 90
Study 17963857 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive with 30 mcg ethinyl estradiol and 2 mg chlormadinone acetate
Number of subjects: 156
Study 17963857 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive with 30 mcg ethinyl estradiol and 3 mg drospirenone
Number of subjects: 156
Study 16251128 — intervention group
Group type: EXPERIMENTAL
Intervention: Isopropyl unoprostone (group II, 1 hr before aspiration)
Number of subjects: 36
Study 16251128 — intervention group
Group type: EXPERIMENTAL
Intervention: Isopropyl unoprostone (group III, 2 hr before aspiration)
Number of subjects: 36
Study 16251128 — intervention group
Group type: EXPERIMENTAL
Intervention: Isopropyl unoprostone (group B, 1 hr before surgery)
Number of subjects: 36
Study 16251128 — intervention group
Group type: EXPERIMENTAL
Intervention: Isopropyl unoprostone (group C, 2 hr before surgery)
Number of subjects: 36
Study 16251128 — intervention group
Group type: EXPERIMENTAL
Intervention: Isopropyl unoprostone (group D, 3 hr before surgery)
Number of subjects: 36
Study 16251128 — intervention group
Group type: EXPERIMENTAL
Intervention: Isopropyl unoprostone (group E, 4 hr before surgery)
Number of subjects: 36
Study 12407615 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine and nimesulide combination
Number of subjects: 0
Study 12407615 — intervention group
Group type: COMPARATOR
Intervention: Epidural bupivacaine/fentanyl combination
Number of subjects: 0
Study 10517037 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release (CR) morphine tablets (every 12 h)
Number of subjects: 18
Study 10517037 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release (IR) morphine tablets (every 6 h)
Number of subjects: 18
Study 8540930 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (rHuEPO) 150 U/kg administered intravenously twice a week for 4 weeks in group A (26 infants)
Number of subjects: 70
Study 8540930 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythrocyte transfusion when hemoglobin levels were less than 10 g/dL with symptoms or less than 8 g/dL in group B (25 infants)
Number of subjects: 70
Study 8540930 — intervention group
Group type: COMPARATOR
Intervention: Non-rHuEPO and nontransfusion group in group C (19 infants)
Number of subjects: 70
Study 2084936 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed minidose warfarin (1 mg daily)
Number of subjects: 0
Study 2084936 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 0
Study 2084936 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (warfarin and placebo)
Number of subjects: 0
Study 31566651 — intervention group
Group type: EXPERIMENTAL
Intervention: Care Ecosystem (telephone-based collaborative dementia care)
Number of subjects: 780
Study 31566651 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 780
Study 30422224 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Health Worker (CHW) intervention with 6 months of tailored support
Number of subjects: 592
Study 30422224 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Health Worker (CHW) intervention
Number of subjects: 592
Study 30422224 — intervention group
Group type: COMPARATOR
Intervention: Control arm (goal setting only)
Number of subjects: 592
Study 27381954 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated questions in online video lectures (Group B)
Number of subjects: 100
Study 27381954 — intervention group
Group type: COMPARATOR
Intervention: Uninterrupted online video lectures (Group A)
Number of subjects: 100
Study 24709016 — intervention group
Group type: EXPERIMENTAL
Intervention: Master Your Mood (MYM) online group course
Number of subjects: 234
Study 22293059 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfacalcidol
Number of subjects: 80
Study 22293059 — intervention group
Group type: EXPERIMENTAL
Intervention: Paricalcitol
Number of subjects: 80
Study 22293059 — intervention group
Group type: COMPARATOR
Intervention: Alfacalcidol and Paricalcitol
Number of subjects: 80
Study 19797501 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 microg ACTH (1‐24) administered in the morning
Number of subjects: 60
Study 19797501 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 microg ACTH (1‐24) administered in the afternoon
Number of subjects: 60
Study 17237126 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional output SCS (3 x 2 h/day, phase A)
Number of subjects: 12
Study 17237126 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional output SCS (24 h/day, phase B)
Number of subjects: 12
Study 17237126 — intervention group
Group type: EXPERIMENTAL
Intervention: Subthreshold output SCS (3 x 2 h/day, phase C)
Number of subjects: 12
Study 17237126 — intervention group
Group type: COMPARATOR
Intervention: Low-output (placebo) SCS (24 h/day, phase D)
Number of subjects: 12
Study 15924803 — intervention group
Group type: EXPERIMENTAL
Intervention: Xuezhikang (0.6 g Bid)
Number of subjects: 4870
Study 11978847 — intervention group
Group type: EXPERIMENTAL
Intervention: [11C]NNC 112 (D1 receptor antagonist)
Number of subjects: 32
Study 11978847 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 32
Study 9621761 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity at the workplace
Number of subjects: 0
Study 9621761 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 7649665 — intervention group
Group type: EXPERIMENTAL
Intervention: Terminalia Arjuna (500 mg 8-hourly)
Number of subjects: 12
Study 7649665 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2704583 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (10 mg/kg)
Number of subjects: 16
Study 2704583 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 362141 — intervention group
Group type: EXPERIMENTAL
Intervention: RA27/3 rubella vaccine (Almevax)
Number of subjects: 0
Study 362141 — intervention group
Group type: COMPARATOR
Intervention: Cendehill vaccine (Cedevax)
Number of subjects: 0
Study 31504897 — intervention group
Group type: EXPERIMENTAL
Intervention: Family‐centered intervention program (FCIP)
Number of subjects: 251
Study 31504897 — intervention group
Group type: COMPARATOR
Intervention: Usual care program (UCP)
Number of subjects: 251
Study 29029224 — intervention group
Group type: EXPERIMENTAL
Intervention: HZ/su vaccine coadministered with IIV4
Number of subjects: 828
Study 29029224 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving IIV4 followed by HZ/su
Number of subjects: 828
Study 25516405 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention with DVD and written materials
Number of subjects: 261
Study 25516405 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention with social support groups
Number of subjects: 261
Study 25516405 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 261
Study 23991916 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-transplantation anemia (PTA)
Number of subjects: 2102
Study 22013790 — intervention group
Group type: EXPERIMENTAL
Intervention: Dengzhan Xixin Injection + Chinese decoction + Dengzhan Shengmai Capsule + acupuncture + massage + external washing with Chinese medicine
Number of subjects: 99
Study 22013790 — intervention group
Group type: EXPERIMENTAL
Intervention: Kudiezi Injection + Chinese decoction + Naoshuantong Capsule + acupuncture + massage + external washing with Chinese medicine
Number of subjects: 99
Study 22013790 — intervention group
Group type: COMPARATOR
Intervention: Western medicine control (rehabilitation training and electronic stimulus)
Number of subjects: 99
Study 18203894 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g UHV-HPMC
Number of subjects: 50
Study 18203894 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g HV-HPMC
Number of subjects: 50
Study 18203894 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g HV-HPMC
Number of subjects: 50